Unknown

Dataset Information

0

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).


ABSTRACT:

Purpose

A protocol was developed to evaluate the value of an NK-1 receptor antagonist for preventing nausea and vomiting resulting from highly emetogenic chemotherapy when an olanzapine-based antiemetogenic regimen was used.

Materials and methods

A221602, a prospective double-blind, placebo-controlled clinical trial, was developed to compare 2 -olanzapine-containing antiemetic regimens, one with an NK-1 receptor antagonist (aprepitant or fosaprepitant) and one without. Trial patients had a malignant disease for which they received intravenous highly emetogenic chemotherapy (single day cisplatin ≥ 70 mg/m2 or doxorubicin plus cyclophosphamide on 1 day). Patients on both arms received commonly administered doses of a 5-HT3 receptor antagonist, dexamethasone, and olanzapine. Additionally, patients were randomized to receive an NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV) or a corresponding placebo. The primary objective was to compare the proportion of patients with no nausea for 5 days following chemotherapy between the 2 study arms. This trial was designed to test for the noninferiority of deleting the NK-1 receptor antagonist, with noninferiority defined as a decrease in freedom from nausea by less than 10%.

Results

A total of 690 patients were entered on this trial, 50% on each arm. The proportion of patients without nausea for the complete 5-day study period was 7.4% lower (upper limit of the one-sided 95% confidence interval was 13.5%) in the arm without an NK-1 receptor antagonist compared with the arm with an NK-1 receptor antagonist.

Conclusion

This trial did not provide sufficient evidence to support that deletion of the NK-1 receptor antagonist was as good as keeping it, as a part of a 4-drug antiemetic regimen for highly emetogenic chemotherapy (ClinicalTrials.gov Identifier: NCT03578081).

SUBMITTER: Navari RM 

PROVIDER: S-EPMC10400142 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).

Navari Rudolph M RM   Le-Rademacher Jennifer J   Smieliauskas Fabrice F   Ruddy Kathryn J KJ   James Saphner Thomas T   Liu Heshan H   Harlos Elizabeth E   Onitilo Adedayo A AA   Giridhar Karthik K   Paul Singh Preet P   Reddy Pavan S PS   Chow Selina S   Kruter Flavio F   Raptis George G   Loprinzi Charles L CL  

The oncologist 20230801 8


<h4>Purpose</h4>A protocol was developed to evaluate the value of an NK-1 receptor antagonist for preventing nausea and vomiting resulting from highly emetogenic chemotherapy when an olanzapine-based antiemetogenic regimen was used.<h4>Materials and methods</h4>A221602, a prospective double-blind, placebo-controlled clinical trial, was developed to compare 2 -olanzapine-containing antiemetic regimens, one with an NK-1 receptor antagonist (aprepitant or fosaprepitant) and one without. Trial patie  ...[more]

Similar Datasets

| S-EPMC10314477 | biostudies-literature
| S-EPMC5947448 | biostudies-literature
| S-EPMC4684151 | biostudies-literature
| S-EPMC5344450 | biostudies-literature
| S-EPMC10469631 | biostudies-literature
| S-EPMC8488783 | biostudies-literature
| S-EPMC7523353 | biostudies-literature
| S-EPMC6900104 | biostudies-literature
| S-EPMC9098704 | biostudies-literature
| S-EPMC6287343 | biostudies-literature